260 related articles for article (PubMed ID: 31916770)
1. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
3. Single-antibody, targeted nanoparticle delivery of camptothecin.
Han H; Davis ME
Mol Pharm; 2013 Jul; 10(7):2558-67. PubMed ID: 23676007
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
[TBL] [Abstract][Full Text] [Related]
5. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers.
Han H; Davis ME
Bioconjug Chem; 2013 Apr; 24(4):669-77. PubMed ID: 23461746
[TBL] [Abstract][Full Text] [Related]
7. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
[TBL] [Abstract][Full Text] [Related]
8. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue.
Saucier-Sawyer JK; Deng Y; Seo YE; Cheng CJ; Zhang J; Quijano E; Saltzman WM
J Drug Target; 2015; 23(7-8):736-49. PubMed ID: 26453169
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
[TBL] [Abstract][Full Text] [Related]
14. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
15. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
Wang W; He H; Marín-Ramos NI; Zeng S; Swenson SD; Cho HY; Fu J; Beringer PM; Neman J; Chen L; Schönthal AH; Chen TC
Neuro Oncol; 2021 Oct; 23(10):1656-1667. PubMed ID: 33659980
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
[TBL] [Abstract][Full Text] [Related]
17. Prodrug Delivery Using Dual-Targeting Nanoparticles To Treat Breast Cancer Brain Metastases.
Ju X; Chen H; Miao T; Ni J; Han L
Mol Pharm; 2021 Jul; 18(7):2694-2702. PubMed ID: 34109794
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
19. Dual-modified natural high density lipoprotein particles for systemic glioma-targeting drug delivery.
Cui L; Wang Y; Liang M; Chu X; Fu S; Gao C; Liu Q; Gong W; Yang M; Li Z; Yu L; Yang C; Su Z; Xie X; Yang Y; Gao C
Drug Deliv; 2018 Nov; 25(1):1865-1876. PubMed ID: 30474437
[TBL] [Abstract][Full Text] [Related]
20. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood-tumor barrier for boosted brain tumor therapy.
Mu R; Sun H; Zeng Y; Tong Y; Tang P; Zhao M; Lv Z; Yu J; Chen Y; Lan Q; Zhen X; Han L
J Control Release; 2024 May; 369():458-474. PubMed ID: 38575077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
